Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and use in developing personalized cancer treatment. Offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers Provides immediately actionable information ? and hopefully also inspiration ? to move discovery and clinical application forward Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers
| List of Contributors |
|
ix | |
| Preface |
|
xiii | |
| Part I: Foundations of Biomarker Research |
|
|
1 Nuts and Bolts of Biomarker Research |
|
|
3 | (13) |
|
|
|
|
|
2 Cancer Genome Methylation: Biology, Biomarker and Therapeutic Opportunities |
|
|
16 | (11) |
|
|
|
|
|
|
|
|
|
3 MicroRNA Biomarkers for Early Detection of Cancer |
|
|
27 | (10) |
|
|
|
|
|
|
|
4 Inflammation and Cancer |
|
|
37 | (13) |
|
|
|
|
|
|
|
5 Exosomes: A Valuable Biomedical Tool in Biomarker Discovery and Development |
|
|
50 | (14) |
|
|
|
|
|
|
|
6 Epithelial-to-Mesenchymal Transition (EMT): Clinical Implications |
|
|
64 | (13) |
|
|
|
|
| Part II: State-of-the-Science in Organ-Specific Biomarker Research |
|
|
|
|
77 | (16) |
|
|
|
|
|
|
|
|
|
93 | (11) |
|
|
|
|
|
|
|
|
|
|
|
9 Esophageal Cancer Biomarkers |
|
|
104 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
10 Predictive Biomarkers for Therapy in Adenocarcinoma of the Upper Digestive Tract |
|
|
118 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
130 | (11) |
|
|
|
|
|
|
|
141 | (10) |
|
|
|
13 Prognostic and Predictive Biomarkers for Colorectal Cancer |
|
|
151 | (12) |
|
|
|
|
|
|
|
|
|
|
|
14 Early Detection of Lung Cancer |
|
|
163 | (22) |
|
|
|
|
|
|
|
|
|
|
|
|
|
15 Commonalities in Lung Cancer and COPD |
|
|
185 | (12) |
|
|
|
|
|
|
|
197 | (12) |
|
|
|
|
|
|
| Part III: Biomarkers, Screening and Precision Health: Implications for Public Health |
|
|
17 Improving the Clinical Validity of Biomarker Research in Cancer Detection |
|
|
209 | (11) |
|
|
|
18 Cancer Overdiagnosis, Ramifications and Research Strategies |
|
|
220 | (11) |
|
|
|
|
|
19 Predictive Markers and Driver Genes From Treatment Trials: Potential Utility For Early Diagnosis |
|
|
231 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20 Statistical Consideration in Predictive and Prognostic Markers |
|
|
245 | (11) |
|
|
|
|
|
21 Clinical Validation of Molecular Biomarkers in Translational Medicine |
|
|
256 | (11) |
|
|
|
|
|
22 Cancer Biomarker Assays: Performance Standards |
|
|
267 | (10) |
|
|
|
|
|
23 Bioethics and Cancer Biomarker Research |
|
|
277 | (6) |
|
|
|
|
|
|
|
24 Colon Cancer Screening |
|
|
283 | (14) |
|
|
|
|
|
|
| Index |
|
297 | |
Edited by Sudhir Srivastava, Ph.D., MPH Senior Scientific Officer, Chief, Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Translational Oncology Series Series Editors ROBERT C. BAST, MD, Vice President for Translational Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
MAURIE MARKMAN, MD, Senior Vice President for Clinical Affairs, Cancer Treatment Centers of America, Clinical Professor of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
ERNEST HAWK, MD, MPH, Vice President, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
